Early belimumab accelerates renal response and reduces glucocorticoid exposure in lupus nephritis: a multicenter propensity-matched study
Clicks: 1
ID: 315019
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #111 of 200 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 200 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVE: International guidelines recommend early combination of standard therapy with innovative agents in lupus nephritis (LN) to prevent kidney damage. Whether this accelerates renal response is unclear. We aimed to compare renal response trajectories, predictors, glucocorticoid (GC) burden in LN patients receiving early belimumab plus standard-of-care (SoC) vs SoC alone. METHODS: Consecutive adult patients with biopsy-proven LN treated with belimumab plus SoC as initial therapy were enrolled from Italian lupus referral centers and compared with a historical SoC cohort (1990-2016). Data were collected at baseline and during follow-up. Propensity score matching based on baseline proteinuria, eGFR, standard initial treatment and histological class led to comparable groups. Complete renal response (CRR) was defined per 2019 EULAR/EDTA. Cox regression was used to assess predictors. RESULTS: 91 belimumab patients were matched to 91 SoC patients. At 6 months, CRR was higher in the belimumab group (35.9% vs 16.5%, OR (95% CI): 2.81 (1.30-6.29), p= 0.005), while response rates at 12 months were similar (p= 0.87). Time-to-CRR was shorter with belimumab (5.64 (4.08-7.80) vs 7.92 (5.28-11.04) months, p< 0.01). At CRR, GC dose was lower in the belimumab group (5 [5-15] vs 15 [10-20] mg/day, p= 0.018). Independent predictors of earlier CRR were baseline proteinuria (hazard ratio (HR) per g/24h increase (95% CI): 0.89 (0.80-0.98), p= 0.019) and belimumab use (1.70 (1.11-2.62), p= 0.016). CONCLUSIONS: Early belimumab combination therapy accelerates CRR and reduces GC exposure. Achieving early CRR with lower GC is a key target to limit kidney and GC-related damage, supporting early belimumab integration in LN management.
| Reference Key |
openalex_W7162406821
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Mariele Gatto, Claudio Cruciani, Marta Calatroni, Valentina Binda, Claudia Furlan, Martina Uzzo, Elisa Bellis, Elena Bartoloni, Rossella De Angelis, Carlo Salvarani, C Tani, Marta Mosca, Giacomo Emmi, Giovanni Adami, Leonardo Caroti, Micaela Fredi, P Esposito, Simone Negrini, M Piga, Alberto Cauli, F Conti, Alessandra Bortoluzzi, C Montecucco, P. Faggioli, Luca Moroni, Gabriele Gallina, Domenico Santoro, Annamaria Iagnocco, Marco Allinovi, Paride Fenaroli, Alberto Lo Gullo, Luca Iaccarino, R Sinico, Andrea Doria, Gabriella Moroni |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag269
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.